# UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

> **NCT03474497** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Megan Daly, MD** · enrollment: 18 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Metastatic Melanoma
- Metastatic Renal Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** IL-2
- **DRUG:** Pembrolizumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03474497
- **Lead sponsor:** Megan Daly, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-20
- **Primary completion:** 2025-04-22
- **Final completion:** 2026-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474497, "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03474497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*